DOCK11 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the human ovarian carcinoma cell line A2780, designed for the disruption of the DOCK11 gene across a heterogeneous cell pool. This loss-of-function model circumvents clonal selection and instead provides a bulk population with varied knockout efficiencies, suitable for functional assays where polyclonal responses are informative. By abolishing DOCK11 protein expression, researchers can interrogate its role in actin cytoskeletal reorganization, directional cell migration, and related signal transduction cascades governed by the small GTPase CDC42.
The A2780 cell line is an epithelial ovarian carcinoma model established from an untreated patient, extensively utilized as a system for studying ovarian cancer biology. These cells retain genetic and phenotypic features characteristic of high-grade serous ovarian cancer, including dysregulated migration and invasion programs. A2780 cells respond robustly to chemokine and integrin cues that modulate actin dynamics, rendering them a pertinent host for dissecting pathways orchestrated by DOCK11 and its molecular interactors.
DOCK11 functions as a guanine nucleotide exchange factor (GEF) that specifically activates CDC42 by facilitating GDP-to-GTP exchange. Activation occurs downstream of upstream regulators such as the chemokine receptor CXCR4 and integrin receptors, often in cooperation with the adaptor proteins ELMO1 and ELMO2. Active CDC42 subsequently triggers a kinase cascade involving PAK1 and the nucleation-promoting factor WASP, which drives actin polymerization and filopodia formation. Through these interactions, DOCK11 serves as a pivotal node linking extracellular guidance signals to cytoskeletal remodeling and cell motility.
In A2780 cells, DOCK11-dependent CDC42 activation is implicated in tumor cell migration and invasive capacity. Disruption of the DOCK11?CELMO?CCDC42 signaling axis in this polyclonal knockout population impairs actin remodeling and attenuates migratory responses to chemokine and integrin stimuli. This model therefore enables investigation into how ovarian carcinoma cells co-opt immune-cell-like trafficking machinery to undergo metastasis, and provides a tool for assessing the contribution of DOCK11 to ovarian cancer progression and dissemination.
Common research applications include transwell migration and invasion assays to quantify cell motility, immunofluorescence staining for F-actin to visualize cytoskeletal architecture, and pull-down assays for active CDC42 to measure GEF activity. The polyclonal knockout cells are also amenable to co-immunoprecipitation studies of the ELMO?CDOCK11 complex, flow cytometric analysis of surface receptor expression, and drug-target validation for anti-metastatic strategies. For additional information or tailored experimental guidance, please contact Ascent Research.
